BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LigaChem Biosciences\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies LigaChem Biosciences\, Inc.'s dru
 gs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05941507-2589@assetmemo.bio
DTSTAMP:20261121T005939Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:LCB84: Phase 1/2 readout est. (NCT05941507)
DESCRIPTION:LCB84\, phase 1/2.\nStudy: A Study to Evaluate TROP2 ADC LCB84 
 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tum
 ors\nEstimated primary completion: January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/lcb84#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05941507
URL:https://assetmemo.bio/drug/lcb84#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
